无症状早期慢性淋巴细胞白血病国际预后评分的外部验证及替代评分提案
Most patients with chronic lymphocytic leukaemia (CLL) are nowadays diagnosed without any symptoms and do not require therapy. A prognostic score identifying patients within this large group who are at high risk of disease progression would be highly beneficial.…
要点
- AIPS-E评分用细胞遗传学异常替代淋巴结肿大,同样有效。
- 两评分均能区分早期CLL患者的疾病进展风险。
核心结论
- 成功验证IPS-E评分可用于早期无症状CLL患者的预后分层。
- 提出结合IGHV、FISH和ALC的AIPS-E评分作为替代方案。
研究设计与样本
- 外部验证研究:连续纳入130例Binet A期CLL患者验证IPS-E。
- AIPS-E在388例来自五个捷克中心的Binet A期患者中外部验证。
主要发现
- AIPS-E低、中、高危组5年TTFT分别为14%、40%、72%。
关键数值与推荐
- IPS-E使用ALC >15×10^9/l、可触及淋巴结肿大和IGHV未突变。
- AIPS-E使用细胞遗传学异常替代可触及淋巴结肿大。
临床怎么用
- IPS-E可用于早期无症状CLL患者的进展风险分层。
- AIPS-E可作为替代评分,尤其适用于以FISH结果替代淋巴结评估时。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most patients with chronic lymphocytic leukaemia (CLL) are nowadays diagnosed without any symptoms and do not require therapy. A prognostic score identifying patients within this large group who are at high risk of disease progression would be highly beneficial. The recently published International Prognostic Score for Early asymptomatic patients (IPS-E) uses combination of absolute lymphocyte count (ALC) >15 × 109 /l, palpable lymphadenopathy, and unmutated immunoglobulin heavy-chain variable-region (IGHV) gene to predict the time to first-line therapy (TTFT). Patients at low, intermediate, and high risk had estimated 5-year TTFT of 8%, 28%, and 61%. We performed an external validation of the IPS-E score using an unselected, consecutive group of 130 Binet A patients. The 5-year TTFT was 11%, 36%, and 78% (C-statistic 0·74). Furthermore, we propose an alternative system (AIPS-E) using cytogenetic aberrations instead of palpable lymphadenopathy. This system yielded 5-year TTFT of 14%, 40%, and 72%. These results were externally validated in 388 Binet A patients from five Czech centres; the 5-year TTFT was 16%, 37%, and 80% (C-statistic 0·74). In conclusion, we have successfully validated the IPS-E score for patients with early stage CLL. In addition, we propose a modified scoring system, the AIPS-E, combining IGHV, fluorescence in situ hybridisation, and ALC.
引用
- Smolej L, Turcsányi P, Kubová Z, et al. External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. Br J Haematol. 2020. PMID: 33280081. doi:10.1111/bjh.17074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。